STAT+: AstraZeneca sues to immediately stop Medicare drug price negotiation program
WASHINGTON — AstraZeneca is the sixth drug maker to pile on a legal challenge to the Biden administration’s drug pricing reform law, and the first to ask a court to immediately stop the law from going into effect.
The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.
AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge for a preliminary injunction to immediately stop the program from going into effect. No other drug maker has made that request, though the Chamber of Commerce did ask a court in Ohio for an immediate stop to the law.
